MOTS-c: The Mitochondrial Peptide Generating Research Interest in Metabolic Disease and Ageing

Key takeaways

• MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) that regulates cellular metabolism primarily through AMPK-dependent pathways; it is distinct from nuclear-encoded peptides in origin and mechanism.
• Preclinical data published in 2025 suggest protective roles for MOTS-c in pancreatic β-cell senescence, diabetic cardiac mitochondrial function, and age-related insulin resistance — but no completed human efficacy trials exist.
• MOTS-c is prohibited at all times under the WADA 2026 Prohibited List as an AMPK activator (Section S4.4.1), and UK Anti-Doping enforces the same prohibition domestically.
• In the United States, MOTS-c is scheduled for evaluation by the FDA's Pharmacy Compounding Advisory Committee at its July 2026 PCAC meeting; it remains ineligible for compounding in the interim.
• In the UK, MOTS-c has no MHRA marketing authorisation; it may be procured for genuine laboratory research under a "research use only" designation, but marketing or supply for human consumption is unlawful under The Human Medicines Regulations 2012.
• Stability data indicate reconstituted MOTS-c is viable for at least 30 days at 4 °C; short in-vivo half-life (estimated at one to two hours) presents a significant pharmacokinetic challenge for any future therapeutic development.

What is MOTS-c and where does it come from?

Most peptides of interest to research procurement professionals are encoded in the nuclear genome. MOTS-c is an exception. It is a 16-amino-acid peptide encoded within the open reading frame of the mitochondrial 12S ribosomal RNA gene, making it one of a small family of mitochondrial-derived peptides (MDPs) that includes humanin and the short humanin-like peptides (SHLP1–6). Its sequence — MRWQEMGYIFYPRKLR — is highly conserved across species, suggesting functional importance rather than evolutionary artefact.

MOTS-c was first characterised by researchers at the University of Southern California in 2015 and has since accumulated a body of preclinical literature exploring its role as a systemic metabolic regulator. As an MDP, MOTS-c is found in blood and mitochondria-containing tissues throughout the body, with circulating levels that decline with age and in states of metabolic disease.

Mechanism of action

The primary signalling node for MOTS-c is AMP-activated protein kinase (AMPK), an energy-sensing enzyme activated when cellular energy is depleted. MOTS-c regulates cellular metabolism through AMPK-dependent pathways, enhancing glucose utilisation and stress responses. Skeletal muscle is the principal target tissue: MOTS-c targets skeletal muscle and can enhance glucose metabolism, a property relevant to insulin resistance and type 2 diabetes research.

Secondary mechanisms include modulation of mTOR signalling. Protein modelling has predicted that the α-helical domain of MOTS-c binds Raptor through side chain-side chain interaction, potentially acting as a competitive inhibitor that prevents the binding of TOR signalling motifs of 4E-BP1, S6K, and PRAS. This mTOR interaction may partly explain observed effects on cellular senescence and immune regulation.

MOTS-c is also exercise-responsive. Exercise induces endogenous MOTS-c expression in skeletal muscle and in human circulation, positioning it as a potential mediator of exercise-related metabolic benefits. This has led some researchers to describe it as an "exercise-mimetic" peptide — one that activates many of the same pathways that physical activity does, including improved endurance and enhanced metabolic flexibility, according to preclinical data.

State of the clinical and preclinical evidence

Preclinical findings (2024–2025)

Recent publications add to the existing body of animal-model data:

Pancreatic β-cell protection. A 2025 study published in Experimental & Molecular Medicine showed that MOTS-c levels decrease with ageing and senescence in pancreatic islet cells. Treating aged mouse pancreatic islets with MOTS-c reduced senescence markers and improved glucose intolerance in nonobese diabetic mice. Notably, circulating MOTS-c levels are lower in type 2 diabetes patients compared with healthy controls, a finding that has now been replicated across several independent cohorts.

Diabetic cardiac function. A 2025 paper in Frontiers in Physiology investigated whether MOTS-c therapy can restore mitochondrial bioenergetic function in the type 2 diabetic heart, where mitochondrial dysfunction has been linked to decreased contractile performance. The investigators found that exogenous MOTS-c improved mitochondrial respiratory function in a rat model of T2D, consistent with the hypothesis that MDPs can correct the energy deficit underlying diabetic cardiomyopathy.

Age-related physical decline. Earlier research published in Nature Communications demonstrated that late-life intermittent MOTS-c treatment (three times per week) increased physical capacity and healthspan in aged mice, and that exercise induces endogenous MOTS-c expression in humans — reinforcing the exercise-mimetic framing.

Autoimmune diabetes. Research reviewed in the Diabetes & Metabolism Journal showed that MOTS-c treatment delayed the onset of autoimmune diabetes in NOD mice, improved glucose tolerance, and protected pancreatic β-cells against proinflammatory T-cell activity.

Human clinical data: limited and early-stage

MOTS-c is the first mitochondrial-encoded peptide to have been subjected to a clinical trial, but the data that exist are sparse. The MOTS-c analogue CB4211, developed by CohBar, completed Phase 1a/1b studies (NCT03998514) in healthy volunteers and subjects with obesity and fatty liver disease (NAFLD). The Phase 1b portion enrolled 20 obese participants with elevated liver fat: the 25 mg subcutaneous daily dose met its primary safety endpoint over 28 days. However, as of April 2026, no active MOTS-c or MOTS-c analogue trials are registered on ClinicalTrials.gov, indicating that clinical development has stalled. CohBar has not advanced CB4211 beyond Phase 1b.

Researchers and procurement professionals should note that no human efficacy data exist for native MOTS-c itself, and that analogue findings cannot be assumed to translate directly to the parent compound.

Pharmacokinetics and stability: considerations for laboratory use

Stability analyses of exogenous MOTS-c peptides conducted using high-resolution mass spectrometry found that MOTS-c reconstituted in water showed no significant degradation for at least 30 days when stored at 4 °C. Freeze-thaw cycling degrades the peptide; aliquoting prior to freezing at −20 °C is the standard approach for longer storage windows.

The in-vivo half-life presents a more significant pharmacological challenge. Endogenous MOTS-c induced by exercise returns to baseline circulating levels within approximately four hours, suggesting a half-life of one to two hours depending on individual metabolic rates. The biological half-life of exogenous MOTS-c in humans has not been formally established. This short half-life is one of the reasons why stable analogues such as CB4211 were prioritised for clinical development over the native sequence.

Regulatory status: US, UK and anti-doping frameworks

United States (FDA)

MOTS-c holds no FDA approval for any therapeutic indication. In the US compounding framework, it has been classified as a bulk drug substance raising significant safety concerns (Category 2), prohibiting its use by 503A compounding pharmacies. MOTS-c is among the peptides scheduled for evaluation at the FDA's Pharmacy Compounding Advisory Committee meeting on 23–24 July 2026. That PCAC meeting will assess whether to recommend it for inclusion on the 503A Bulks List. A positive recommendation would move MOTS-c to Category 1 — permitting compounding under prescription — but would not constitute FDA approval, and formal rulemaking would still be required before pharmacies could act on such a recommendation.

While the public advisory committee meetings convened in 2024 resulted in the PCAC voting against inclusion of all peptides under review at that time, the current regulatory and political environment may produce a different outcome. Research procurement professionals following the US market should monitor the July docket closely.

United Kingdom (MHRA)

No MHRA marketing authorisation exists for MOTS-c. Under The Human Medicines Regulations 2012, it is illegal to sell any drug or compound for human consumption without MHRA approval. MOTS-c may, however, be lawfully supplied and purchased in the UK for genuine laboratory research under a "research use only" designation, provided it is not marketed with medicinal claims. The MHRA does actively enforce against companies selling unlicensed medicines and has shut down operations that were selling peptides as health supplements. Adverse reactions should be reported via the MHRA Yellow Card scheme.

Unlike the US system, the UK does not operate a formal Category 1/Category 2 compounding classification for peptide bulk substances. The MHRA's focus is on whether a product is marketed as a medicine; a genuinely research-labelled supply chain operates under different scrutiny.

WADA and UK Anti-Doping (UKAD)

MOTS-c is prohibited at all times under Section S4.4 (Metabolic Modulators, Activators of AMPK) of the WADA 2026 Prohibited List, effective 1 January 2026. The 2026 Prohibited List was approved by WADA's Executive Committee in September 2025. UKAD adopts the WADA code domestically. No Therapeutic Use Exemption (TUE) is available for MOTS-c because there is no approved therapeutic use. Research involving subjects who are competitive athletes must account for this prohibition. FDA reclassification proceedings, should they result in a positive PCAC recommendation, would not affect the WADA prohibited status.

Supply chain and quality considerations

Research-grade peptides, including MOTS-c, can vary markedly in purity — with some products reported at as low as 60% peptide content — and may contain endotoxins, truncated sequences, solvent residues, heavy metals, or microbial contamination. Certificates of analysis from unverified suppliers may be issued without actual lot-specific testing, according to industry monitoring. Procurement professionals sourcing MOTS-c for laboratory use should request mass spectrometry confirmation of sequence identity and HPLC purity data ≥ 98%, and verify that the manufacturer operates under appropriate quality standards.

No GMP requirements apply to the grey-market research chemical category, making supplier due diligence the principal quality control mechanism available to research buyers. Lyophilised product should be stored at −20 °C to −80 °C; reconstituted solutions should be used within seven days if held at 2–8 °C, or aliquoted and stored at −20 °C for longer windows.

Outlook

MOTS-c occupies an intriguing but early position in the peptide research landscape. Its mitochondrial origin distinguishes it mechanistically from the nuclear-encoded growth secretagogues and GLP-1 analogues that dominate current regulatory and commercial attention. The 2025 publications on β-cell senescence and diabetic cardiac mitochondria strengthen the scientific rationale for continued investigation, but the absence of active registered trials and the stalling of the CB4211 development programme mean that a clinical therapeutic application remains a distant prospect.

The July 2026 PCAC review will determine whether MOTS-c's US regulatory status improves sufficiently to enable compounded human use. For UK research laboratories, the current position — lawful procurement for in-vitro and in-vivo research, strict prohibition on any human administration or therapeutic claim — is unlikely to change in the short term absent an approved medicinal product, which no company is currently pursuing.